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Indoramin in the treatment of
hypertension
A mini-review and update
J. L. ARCHIBALD, P. TURNER
Summary
The origins, pr-eclinical development a'nd clinical
pharmacology of a new antihypertensive agent,
indoramin (Baratol; Wyeth), are briefly reviewed.
Indoramin is a competitive postsynaptic a-adreno-
ceptor antagonist with a myocardial membrane-
stabilizing component of action. These features are
believed to be responsible for its antihypertensive
efficacy. They may also explain the absence of prob-
lems common to older a-blockers such as reflex
tachycardia and postural hypotension. Clinical ev~­
luation of a new agent such as indoramin in the
management of hypertension is discussed in terms
of efficacy, dosage regimen, tolerance, adverse
effects, interactions, withdrawal syndrome, and
long-term influence on the complications of high
blood pressure.
S Atr Med J 1983: 63: 307-309.
Following the introduction of indoramin (Baratol; Wyeth) for
the treatment of essential hypertension in South Africa, it is
appropriate to provide a brief review and update encompassing
the origins, preclinical development, mode of action and thera-
peutic use of the agent.
Background and origins
Increased peripheral vascular resistance is a major feature of
essential hypertension, and since a-adrenocepror-blocking drugs
reduce peripheral resistance it would theoretically be ideal to use
them. for antihypertensive therapy. 1 In practice, older a-blockers
were little used for this purpose. They tended to be poorly
absorbed after oral administration and to provoke gastro-
intestinal disturbances, reflex tachycardia and postural hypoten-
sion. Alpha-blocker-induced reflex compensatory cardio-accele-
ration also increased cardiac output and therefore tended to
offset any lowering of blood pressure in response to vasodilata-
tion. If these drawbacks could be overcome, antihypertensive
efficacy would be increased and limiting side-effects avoided.
One possible way to accomplish this would be to incorporate a
component of action into an a-blocker that would counteract or
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prevent this reflex response; the mode of action of indoramin
reflects this approach. 2
In the synthesis of indoramin,3 features of two types of mole-
cule were combined. A series ofso-called bis-indoles4 had shown
good antihypertensive activity in which a-blockade was believed
ro have played an important part. Replacement of one indolyl-
ethyl moiety of the bis-indole by a benzamido group gave ri e ro
indoramin, in which a resemblance to procainamide had been
incorporated.; The extent to which an a-blocking action (as in
the bis-indole) and membrane-stabilizing action (as in procam-
amide) had been combined in the new molecule can perhaps be
judged from the following section.
Preclinical development
Indoramin lowered blood pressure effectively in all species stu-
died.6.? It also showed competitive a-adrenoceptor antagonism
in a wide variety of in vitro and in vivo experiments, with for
instance a pA2 value against noradrenaline of 7,4 in the guinea-
pig aorta.s The hypotensive or antihypertensive activity was not
accompanied by tachycardia, which suggested that the a-
blockade might indeed be accompanied by some action preven-
ting reflex stimulation of heart rate. Many experiments indicated
that this was a direct cardioregulatory property involving
myocardial membrane stabilization. For example, indoramin
was shown to be a potent local anaesthetic agent9 and electrophy-
siological studies on canine myocardial strips showed that at
therapeutic plasma concentrations there was a significant
decrease in the rate of depolarization. 10 In vivo evidence of thiS
direct effect on the heart fully supported the results in isolated
tissue, " and indoramin has shown good antidysrhythmic activity
in a variety of experimental situations.9
Another factor contributing ro the lack of tachycardia can now
be understood in terms of knowledge not available at the time
indoramin was conceived. The discovery of presynaptic a-
receptors and negative feedback control of noradrenaline release
enabled us to appreciate that unselective a-blockers will inter-
fere with this negative feedback control and thus allow greater
stimulation of postsynaptic R-receprors in the heart and a-
receptors in the blood vessels. This will contribute ro both an
increase in heart rate and the relative ineffectiveness of unselec-
tive a-blockers in lowering blood pressure. Indoramin avoids
both of these drawbacks by acting specifically at postsynaptic
a,-receptors. TypicalIX the ratio of post- to presynaptic poten-
cies is about I 000: 1. ' .13
Postural hypotension was another major drawback preventing
widespread acceptance of older a-blockers for the treatment of
hypertension. In contrast, the incidence of posrural hypotensIOn
with indoramin is minimal. Probable reasons for this include the
competitive nature of the antagonism, the apparently greater
potency in resistance than in capacitance vessels,S and the lack of
antagonism of postsynaptic a 2-receptors. Animal experiments
involving additional falls in blood pressure on 90° head-up tilt
were fully in accord with clinical experience in this ~espect.
Unlike most other antihypertensive agents studied, indoramin
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caused no such additional falls in blood pressure on head-up tilt,
except at the highest dose tested, which was many times the
maximum human therapeutic dose.2
Indoramin is well absorbed when orally administered, does
not cause gastro-intestinal disturbances and does not provoke
tolerance. In addition, its vasodilator and bronchodilator proper-
ties will allow it to be used on patients for whom some other
antihypertensive treatments are contraindicated, as discussed in
the clinical part of this review.
Clinical pharmacology of indoramin
The following factors should be considered when evaluating a
new drug such as indoramin in the management ofhypertension:
(i) efficacy; (ii) dosage regimen; (iii) tolerance; (iv) short- and
long-term adverse effects; (v) interactions; (vi) withdrawal syn-
drome; and (vii) long-term influence on the complications of
high blood pressure.
Efficacy of indoramin
Although in preliminary single-dose studies in normal sub-
jects indoramin produced an increase in heart rate in association
with a fall in systolic and diastolic blood pressures,14 long-term
studies in hypertensive patients have demonstrated clinically
important falls in blood pressure without any increase in heart
rate,15.16 so confirming the results of animal studies already
described.
Twenty-four-hour records of intra-arterial ambulatory blood
pressure l7 after 6 weeks' treatment ofhypertensive patients with
twice-daily indoramin demonstrated significant reduction in
blood pressure throughout the whole 24-hour period, including
the early-morning phase of rising blood pressure just prior to
awakening.
Comparative studies of indoramin against other antihyperten-
sive drugs are generally lacking, but Yajnik er al. 18 found no
significant difference between indoramin and methyldopa in 89
patients in a controlled trial.
Dosage regimen
Patient compliance is assisted by once- or twice-daily rather
than more frequent administration of a drug. The studies of
Gould er al. 17 already referred ~o have shown that twice-daily
administration of indoramin provides satisfactory 24-hour con-
trol of blood pressure. Treatment should begin with 25 mg twice
daily, increasing by 25 mg increments at not less than 2-week
intervals to a maximum of 75-100 mg/d.
Tolerance
Tolerance may develop to some antihypertensive dru~s, but
long-term treatment with indoramin for 1 year or longer l .17 has
shown no reduction in antihypertensive effectiveness or need for
increased doses. Rather there appears to be a sustained gradual
fall in blood pressure which may make it possible to reduce the
dose of indoramin required to maintain satisfactory control.
methyldopa. 18 A small reduction in dose may lead to its dis-
appearance without reduction in blood pressure control.
Other less frequent adverse effects include weight gain and
fluid retention, headache and depression.
No other significant adverse effects have appeared with pro-
longed use of indoramin. In particular it does not appear to
produce an increase in antinuclear factor or a systemic lupus
erythematosus-type syndrome. Nevertheless, as with all drug
treatment vigilance is required to identify previously unrecog-
nized adverse effects associated with long-term use, particularly
if they are limited to certain groups of patients at special risk.
Interactions with other drugs ..
Several important interactions between antihypertensive and
other drugs are recognized. Drugs that inhibit monoamine reup-
take can antagonize the hypotensive effects of those blocking
adrenergic neurons and of clonidine, but do not appear to in-
fluence the action of indoramin.20 The efficacy of B-adrenergic
blocking drugs and of diuretics can be reduced by non-steroidal
anti-inflammatory drugs,21 but this has not yet been studied with
indoramin. The systemic clearance of some B-adrenoceptor-
blocking drugs is reduced by treatment with cimetidine,22 but it
is not yet known whether a similar interaction occurs between
indoramin and cimetidine.
Withdrawal syndrome
The abrupt withdrawal of some drugs may be associated with
the appearance ofa characteristic syndrome, the most important
among antihypertensive drugs being that following sudden
withdrawal of clonidine.. Se~eral inve~~i90a~ors.have ab.ruptly
dlscontmued treatment with mdoramm .-. Without eVidence
of withdrawal hypertension or any other adverse clinical effects.
Long-term influence on complications of
hypertension
There is now good evidence that long-term control of mode-
rate and severe hypertension, and probably of mild hyperten-
sion, is associated with a fall in morbidity and mortality caused
by high blood pressure,24 and it is probable that indoramin will
have a similar beneficial effect, although this will have to be
demonstrated in prospective studies. It is hoped that its
membrane-stabilizing antidysrhythmic properties may exert a
cardioprotective action. Recent studies (R. Verma, L. Abrams,
P. Turner -personal communication, 1982), using a new tech-
nique for assessing membrane-stabilizing activity in man which
depends on inhibition of human sperm motility in virro,25 have
shown that indoramin is considerably more potent than ligno-
caine and procaine in this respect (Table I). Clinical studies of
the antidysrhythmic properties of indoramin in patients with
different types of dysrhythmia are now in progress, and should
provide important information on this question.
TABLE I. CONCENTRATIONS WHICH DECREASE HUMAN
SPERM MOTILITY TO 50% OF CONTROL VALUES (ECso)
Adverse effects
The most frequently reported adverse effects associated with
the use of indoramin are sedation, dry mouth, dizziness and
failure of ejaculation. 19 Their incidence varies between different
studies and depends on the method by which they are elicited.
Sedation is the most common adverse effect; it is usually mild











Indoramin in the stepwise management of.
hypertension
At present a stepwise approach is generally recommended in the
management ofessential hypertension. One drug is used initially,
followed by the addition of a second if necessary and a third in
those few cases in which control is still not adequate. It is too
early to define with certainty the true place of indoramin in such
therapy, since management is to some extent determined bv
recommendation and experience, as well as changing prescribing
habits. Experience to date with indoramin has been greatest in
second-step therapy. Here it is likely to find a useful place in
association -with a diuretic, especially in patients in whom R-
receptor-blocking drugs are contraindicated because of increased
airways resistance or concurrent vasospastic conditions, or with a
R-blocking drug in patients in whom a thiazide diuretic is con-
traindicated, for example because of gout or diabetes. Such
combined treatment will be associated with smaller doses of
indoramin than in monotherapy, and so with a lower incidence of
sedation and other dose-related adverse effects.
Although evidence for the use of indoramin as sole therapy is
so far less thoroughly substantiated, there are no contraindica-
tions to the latter, provided the dose is not increased too much or
too rapidly. Indoramin may also have a valuable role as third-line
treatment in that relatively small proportion ofpatients who have
not responded satisfactorily to a R-blocking drug plus a diuretic
and in whom a vasodilator would now be considered appropriate.
We thank all our colleagues for their collaboration in preclinical
and clinical studies on indoramin.
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News and Comment/Nuus en Kommentaar
The American Medical Association and
nuclear war
At the meeting of the American Medical Association's House of
Delegates this year, reference was made to the AMA's attitude to
nuclear war. It decided to tell the US President and Congress
that there is no adequate medical response to a nuclear holocaust.
Nevertheless, the Delegates stated that doctors should never be
placed in a position of denying medical care, including the
possible preparation for care and preparation for life-saving
before the event. The resolution adopted states that the AMA
'will prepare material to educate physicians and the public about
the medical consequences of nuclear war; will, with other health
organizations, cooperate with responsible authorities in dealing
with those matters having to do with health and medical care in
the event of national emergencies, including those associated
with military activity; and will not become involved in political
issues outside its professional expertise, such as national defense
and the politics of nuclear war preparedness, as it is not
appropriate for the AMA to do so'.
Not with a whimper but a bang
Cutting for the stone is a well-establj~hed procedure in the
urologist'S repertoire, not so much into the bladder as in Frere
Jacques's day, but more into the kidney itself, although the
kidney's inaccessibility usually makes a large lumbar incision
and considerable dissection necessary, which puts such
operations into the realm of major surgery. A new device called
the lithotripter now makes destruction of kidney stones possible
without operation (Lancet 1982; ii: 1256). This is done by
focusing the shock wave from a high-intensity spark onto the
st0ne, shattering it. Performed under close radiographic control
on patients under epidural anaesthesia immersed in a water-
bath, extracorporeal shock wave lithotripsy (ESWL) has proved
extremely successful; of 100 patients treated with this method so
far, none has subsequently needed open operation.
Even though the necessary apparatus is expensive, this is
offset to some extent by patients being able to leave hospital
within 48 hours. It appears that ESWL will be joining
percutaneous nephrosromy and open operation in the
management of patients with renal stones.
